Johannes Hajos

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jan van den Berg, Louis B. Bartels, H. Heidbuchel, 2022, The Lancet.

Antikoagulation nach Kardioversion

G. Hindricks, S. Kircher, Johannes Hajos, 2012, Kardiologie up2date.

Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry

K. Huber, R. Zweiker, F. Egger, 2017, PloS one.

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.

Jan van den Berg, Louis B. Bartels, H. Heidbuchel, 2022, Lancet.